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POLA HUBUNGAN ANTARA CIRI-CIRI DEMOGRAFI SOSIAL, KLINIKAL DAN 
RAWATAN TUBERKULOSIS RINTANG PELBAGAI UBAT DI ANTARA 




Pengenalan: Kemunculan dan peningkatan jumlah tuberkulosis rintang pelbagai ubat (MDR-
TB) di seluruh dunia telah menimbulkan ancaman kesihatan awam baru di dalam dan di luar 
negara. Terdapat beberapa ciri-ciri pesakit yang penting untuk MDR-TB. Walau 
bagaimanapun, tidak ada kajian yang diterbitkan mengenai hubungan di antara ciri-ciri pesakit 
MDR-TB di Malaysia. 
Objektif: Objektif kajian ini adalah untuk menerangkan ciri-ciri berkaitan demografi, klinikal 
dan rawatan pesakit MDR-TB di Malaysia dan menentukan hubungan di antara faktor-faktor 
penyebab MDR-TB. 
Metodologi: Analisis data sekunder daripada kajian reka bentuk rentas keratan menggunakan 
Sistem Maklumat Tuberkulosis (TBIS) Kementerian Kesihatan Malaysia. Ciri-ciri berkaitan 
demografi, klinikal dan rawatan pesakit MDR-TB diekstrak dari pangkalan data. Analisis log-
linear digunakan untuk mengenal pasti pola hubungan di antara ciri-ciri pesakit MDR-TB 
bersama nisbah odds dan 95% selang keyakinan (SK). 
Keputusan: Terdapat 395 kes MDR-TB yang dilaporkan di seluruh Malaysia dari tahun 2012 
hingga 2016. Odds  pendatang adalah 77% lebih rendah bagi yang berusia tua berbanding 
muda (nisbah odds = 0.23, 95% SK: 0.11, 0.43). Odds jantina lelaki adalah 2.37 kali bagi yang 
berusia tua berbanding muda (nisbah odds = 2.37, 95% SK: 1.45, 3.95). Odds jantina lelaki 
adalah 5.22 kali bagi status HIV positif berbanding status HIV negatif (nisbah odds = 5.22, 
95% SK: 1.48, 33.12). Odds sejarah rawatan TB adalah 78% lebih tinggi bagi jantina lelaki 
xvii 
 
berbanding wanita (nisbah odds = 1.78, 95% SK: 1.13, 2.82) dan 52% lebih rendah bagi status 
ujian kahak positif berbanding status ujian kahak negatif (nisbah odds = 0.48, 95% SK: 0.30, 
0.78) 
Kesimpulan: Analisis log-linear menunjukkan bahawa terdapat hubungan di antara kategori 
umur dan status pendatang, kategori umur dan jantina, jantina dan HIV, jantina dan sejarah 
rawatan TB, dan sejarah rawatan TB dan status ujian kahak. 






THE ASSOCIATION PATTERNS BETWEEN SOCIO-DEMOGRAPHIC, 
CLINICAL AND TREATMENT- RELATED CHARACTERISTICS IN 




Introduction: The emergence and increasing number of multidrug-resistant tuberculosis 
(MDR-TB) worldwide have posed new threats to public health locally and globally. There are 
a number of important patient’s characteristic for MDR-TB. However, there are no studies 
published about association between the characteristics of MDR-TB patient in Malaysia.   
Objective: The objective of this study was to describe the socio-demographic, clinical and 
treatment related characteristics of MDR-TB patients in Malaysia and to determine the 
association patterns between the characteristics of MDR-TB patients in Malaysia 
Methods: Analysis of secondary data from a cross-sectional design study on registry of 
Tuberculosis Information System (TBIS) of Ministry of Health Malaysia. Socio-demographic, 
clinical and treatment related characteristics of MDR-TB patient were extracted from the 
databases. Log-linear regression was used to identify association patterns between the 
characteristics with odd ratios and 95% confidence interval. 
Results: There were 395 cases of MDR-TB reported across Malaysia from 2012 to 2016. Odds 
of immigrant were 77% lower in old age than young age (OR = 0.23, 95% CI: 0.11, 0.43). 
Odds of male gender were 2.37 times in old age group than young age group. (OR = 2.37, 95% 
CI: 1.45, 3.95). Odds of male gender were 5.22 times in HIV positive status group than 
negative HIV status (OR = 5.22, 95% CI: 1.48, 33.12). Odds of previous TB treatment were 
78% higher in male than female (OR = 1.78, 95% CI: 1.13, 2.82) and 52% lower in positive 
sputum status than negative sputum status (OR = 0.48, 95% CI: 0.30, 0.78). 
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Conclusion: Log-linear analysis revealed that there are association between age category and 
immigrant status, age category and gender, gender and HIV, gender and history of previous 
TB treatment, and history of previous TB treatment and sputum status. 
 








Tuberculosis (TB) has existed since 1800s and remains a major global health problem and 
burden (Keshavjee and Farmer, 2012; Frieden et al., 2014; World Health Organization, 2016).  
More than 10 million new cases reported in 2015 and almost two million deaths due to TB 
with about 2 to 3 billion people latently infected despite the fact that TB is curable. (World 
Health Organization, 2016). Figure 1.1 shows 60% of the new cases are contributed by these 
countries: India with the highest numbers, followed by Indonesia, China, Nigeria, Pakistan 
and South Africa. In order to meet their first milestone of the End TB Strategy, WHO has set 
up a target of reduction of 4% to 5% annually worldwide by 2020. However, the rate of decline 
persisted at 1.5% from 2014 to 2015 with major steps need to be done in TB prevention and 
care worldwide especially in these countries (World Health Organization, 2016). 
 
Figure 1.1  The estimated TB incidence rate in 2015
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Tuberculosis is caused by the rod-shaped, non–spore-forming, aerobic 
bacterium Mycobacterium tuberculosis (MTB) (Knechel, 2009; Keshavjee and Farmer, 
2012). It is transmitted via small airborne droplets and usually formed by the action of talking, 
coughing, sneezing or even singing by an individual with pulmonary or laryngeal tuberculosis 
(Knechel, 2009; Turner and Bothamley, 2015).  The presence of MTB in the lungs leads to 
respiratory system infection causes pulmonary tuberculosis and the bacterium may also spread 
to other organs in the body and thus causing extrapulmonary tuberculosis (Knechel, 2009).  
Majority of those who inhaled the droplets containing MTB would develop an effective 
acquired immune response leading to successful inhibition of MTB growth and thus leads to 
bacteria becoming latent; this is called latent TB infection (LTBI) (Fogel, 2015).  They do not 
transmit the disease to others nor present any symptoms (Cruz-Knight and Blake-Gumbs, 
2013). On the other hand, those with active TB have primarily respiratory symptoms such as 
cough, chest pain and haemoptysis and systemic symptoms such as fever, night sweat and 
weight loss (Knechel, 2009; Maher, 2009; Zaman, 2010). 
For treatment of a new case, an intensive regimen of a total of six months is recommended 
(Fox et al., 1999). Daily dose of isoniazid, rifampicin, pyrazinamide and streptomycin (or 
ethambutol if streptomycin is contraindicated) is given for two months and followed by four-
month maintenance regimen of daily isoniazid and rifampicin.  By giving  medications and 
monitoring the patients directly via Directly Observed Therapy Short Course (DOTS) 
programme, it can ensure better success rate of eliminating the disease by more than 85% 
(Blumberg et al., 2005; World Health Organization, 2016). 
1.2 Multidrug-resistant Tuberculosis 
However, the emergence and increasing number of multidrug-resistant tuberculosis (MDR-
TB) worldwide have posed new threats to public health locally and globally (Dheda et al., 
2017). Based on Global Tuberculosis Report in 2016, almost half a million-people developed 
MDR-TB and in Malaysia, MDR-TB cases are accounted for 3.1% in previously treated TB 
cases (World Health Organization, 2016). 
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MDR-TB can be defined as MTB with resistance to at least two most powerful first-line anti-
TB drugs which are rifampicin and isoniazid (McBryde et al., 2017). The resistance may arise 
either by transmission of MDR strain by infected person to another, or by insufficient 
treatment of individual who has been infected with non-resistant strain or only one single drug 
resistant (Faustini et al., 2006). The inadequate drug treatment will allow the growth of small 
number of resistant MTB by spontaneous mutation and subsequently leads to MTB being 
resistance to many drugs (Faustini et al., 2006). 
1.3 Epidemiology of MDR-TB 
1.3.1 Global Situation 
In 2016, WHO estimated incidence cases of MDR-TB to be approximately 490,000. As 
depicted in Figure 1.2, the South-East Asia, Europe and Western Pacific regions contribute 
37%, 23% and 18% respectively of the total global new cases of MDR-TB. These three regions 
contribute the largest number of MDR-TB incidence globally.  
 





With reference to Figure 1.3, the top three countries with largest number of cases are populous 
countries led by India with 147,000 cases, followed by China with 73,000 cases and Russian 
Federation with 63,000 cases which contribute to nearly half of global total. 
Moreover, according to a report published in The Lancet Infectious Diseases, the number of 
MDR-TB are predicted to increase in India, the Philippines, Russia and the South Africa, 
countries which already have a high burden (Sharma et al., 2017). This is estimated from 
mathematical model derived from data of WHO reports and drug resistance survey from the 
respective countries. 
 
Figure 1.3 The estimated incidence of MDR/RR-TB in 2016 by WHO, for countries with at 
least 1000 incident cases(World Health Organization, 2016) 
 
Also, there is a wide gap between detection and the start of MDR-TB treatment where only 
22% of the estimated incidence of MDR/RR-TB cases started treatment in 2016. Most 
significantly, closing this wide gap requires progress in a subset of countries especially China 
and India because both countries are responsible for 39% of the total gaps (World Health 
Organization, 2017). In addition, it has been estimated by the same governing body that 4.1% 
of new cases and 19% of previously treated cases have MDR/RR-TB (World Health 
Organization, 2017).  
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As mentioned previously, the treatment success rate is quite low for MDR-TB as compared to 
TB.  This is evident in the case of death from MDR/RR-TB where almost 240,000 deaths have 
been reported in 2016 (World Health Organization, 2017).  
1.3.2 Situation in Malaysia 
Figure 1.4 reveals that there has been a gradual increase in the number of MDR-TB cases in 
Malaysia from 2004 till 2010. Then, a sharp rise on the number of cases seen and peaked in 
2011 with 141 cases. The figure also shows that in 2015, 101 cases of MDR-TB were reported. 
The MDR-TB burden for Malaysia in term of its incidence rate is estimated to be 1.8 cases per 
100 000 population. Moreover, it has been estimated that 1.5% of new cases and 3.1% of 
previously treated TB cases have MDR-TB. Furthermore, Malaysia has a lower treatment 
success rate of 32% as compared to global success rate (54%) based on the cohort study 
conducted in 2014 (World Health Organization, 2017). 
 
Figure 1.4 MDR-TB Cases in Malaysia from 2004 to 2015(Ministry of Health Malaysia, 2016)  
 
1.4 Tuberculosis Information System (TBIS) Registry  
TBIS is an electronic record system that ensures notifications and records of each of TB patient 
are standardised. This allows continuous monitoring in term of treatment success and overall 
performance of national TB control programme. 
Figure 1.5 shows TB surveillance system in Malaysia. All TB cases including MDR-TB cases 
must be immediately notified to district, state TB organiser team and TB/Leprosy Sector via 
